At the news
? BULLISHIMPACT 7/10 8-K filed Aug 5, 2026 at 07:15 ET
Charles River Laboratories reported Q2 2026 revenue of $1.00B (down 2.7% reported / +0.1% organic YoY) and non-GAAP EPS of $3.02, beating consensus estimates of $2.73 by 10.6%. The company raised its full-year organic revenue guidance to 0.0%-1.0% (from -1.5% to -0.5%) and its non-GAAP EPS guidance to $11.15-$11.45, driven by improving demand in DSA and better-than-expected Manufacturing performance. This marks the first quarter of organic revenue growth since Q3 2023 and signals a potential inflection in underlying demand trends.
- Q2 2026 total revenue $1.00B vs consensus $977.2M; organic revenue grew 0.1% YoY (first positive since Q3 2023)
- Non-GAAP EPS $3.02 beats consensus of $2.73 by 10.6% (down 3.2% from $3.12 a year ago)
- Raised 2026 organic revenue guidance to 0.0%-1.0% from (1.5%)-(0.5%) and non-GAAP EPS to $11.15-$11.45 from $10.80-$11.30
- GAAP net loss of $(0.03)/share driven by $63.7M loss on CDMO & Cell Solutions divestiture completed in May 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access